Proemend fosaprepitant meglumine regulatory update

Ono submitted a regulatory application in Japan for Proemend fosaprepitant meglumine to treat chemotherapy-induced nausea and vomiting (CINV) in pediatric patients ages >=6 months. The injectable formulation of the selective neurokinin 1 (NK1) receptor antagonist is marketed to treat CINV in adults and to treat digestive symptoms resulting from the administration of antineoplastic agents. ...